Clinical TrialsPelareorep continues to progress well in hormone receptor-positive, HER2-negative metastatic breast cancer and metastatic pancreatic ductal adenocarcinoma, with potential to advance to registration-enabling trials.
PartnershipsBusiness development efforts remain active, with potential for non-dilutive capital through global or regional partnerships.
Regulatory ProgressFollowing positive feedback from the FDA, Oncolytics Biotech plans to launch a Phase 2 study in breast cancer with the intent of seeking accelerated approval.